A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival
Abstract Cytokines are involved in the pathogenesis of multiple myeloma (MM) and other cancers. The aim of this study was to evaluate a range of cytokines of diverse activity in patients with multiple myeloma for a possible prognostic value. Concentrations of the following cytokines and cytokine receptors were measured by ELISA in the sera of 64 untreated MM patients: IL-6, IL-8, IL-10, TNFα, sTNF R I and II, sIL-2Rα, IL-1ra, M-CSF, G-CSF, VEGF, and bFGF. Serum levels of sTNF RI, IL-6, and bFGF were elevated in over 50% of patients. There was an inverse relationship between sTNF RII, TNFα, IL-1ra, and albumin levels. There was no significant relationship between cytokines/cytokine receptors and other serum correlates of myeloma. In a univariate survival analysis, β2-microglobulin, LDH, sIL-2Rα, sTNF RI, and M-CSF were significant variables. In a multivariate analysis, only M-CSF and β2-microglobulin retained a significant influence on survival. Serum M-CSF may be considered another independent and clinically useful prognostic factor in multiple myeloma..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2009 |
---|---|
Erschienen: |
2009 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Medical oncology - 28(2009), 1 vom: 31. Dez., Seite 194-198 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kowalska, Maria [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
doi: |
10.1007/s12032-009-9403-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR023870109 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR023870109 | ||
003 | DE-627 | ||
005 | 20230519132716.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201006s2009 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12032-009-9403-9 |2 doi | |
035 | |a (DE-627)SPR023870109 | ||
035 | |a (SPR)s12032-009-9403-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.81 |2 bkl | ||
100 | 1 | |a Kowalska, Maria |e verfasserin |4 aut | |
245 | 1 | 2 | |a A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival |
264 | 1 | |c 2009 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Cytokines are involved in the pathogenesis of multiple myeloma (MM) and other cancers. The aim of this study was to evaluate a range of cytokines of diverse activity in patients with multiple myeloma for a possible prognostic value. Concentrations of the following cytokines and cytokine receptors were measured by ELISA in the sera of 64 untreated MM patients: IL-6, IL-8, IL-10, TNFα, sTNF R I and II, sIL-2Rα, IL-1ra, M-CSF, G-CSF, VEGF, and bFGF. Serum levels of sTNF RI, IL-6, and bFGF were elevated in over 50% of patients. There was an inverse relationship between sTNF RII, TNFα, IL-1ra, and albumin levels. There was no significant relationship between cytokines/cytokine receptors and other serum correlates of myeloma. In a univariate survival analysis, β2-microglobulin, LDH, sIL-2Rα, sTNF RI, and M-CSF were significant variables. In a multivariate analysis, only M-CSF and β2-microglobulin retained a significant influence on survival. Serum M-CSF may be considered another independent and clinically useful prognostic factor in multiple myeloma. | ||
650 | 4 | |a Multiple myeloma |7 (dpeaa)DE-He213 | |
650 | 4 | |a Cytokine |7 (dpeaa)DE-He213 | |
650 | 4 | |a M-CSF |7 (dpeaa)DE-He213 | |
650 | 4 | |a Prognostic factor |7 (dpeaa)DE-He213 | |
700 | 1 | |a Kaminska, Janina |e verfasserin |4 aut | |
700 | 1 | |a Fuksiewicz, Malgorzata |e verfasserin |4 aut | |
700 | 1 | |a Kotowicz, Beata |e verfasserin |4 aut | |
700 | 1 | |a Chechlinska, Magdalena |e verfasserin |4 aut | |
700 | 1 | |a Druzd-Sitek, Agnieszka |e verfasserin |4 aut | |
700 | 1 | |a Walewski, Jan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medical oncology |d New York, NY : Springer, 1984 |g 28(2009), 1 vom: 31. Dez., Seite 194-198 |w (DE-627)SPR023865016 |w (DE-600)2008172-8 |x 1559-131X |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2009 |g number:1 |g day:31 |g month:12 |g pages:194-198 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12032-009-9403-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
936 | b | k | |a 44.81 |q ASE |
951 | |a AR | ||
952 | |d 28 |j 2009 |e 1 |b 31 |c 12 |h 194-198 |